Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma

Exclusion Criteria

• •1. Central nervous system lymphoma was excluded;
• •2. Suffering from serious complications or severe infection;
• •3. A history of other malignant tumors within 5 years, excluding early tumors treated for curative purposes;
• •4. Patients with uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases, etc.;
• •5. HBsAg, HCV or HIV positive. Positive HBV and HCV serology is allowed, but DNA/RNA testing must be negative;
• •6. Laboratory test value during screening;
• •① Neutrophils \<1.5×109/L; Platelet \<75×109/L;
• •② Bilirubin was 1.5 times higher than the normal upper limit, transaminase was 2.5 times higher than the normal upper limit;
• •③ The creatinine level is higher than 1.5 times the upper limit of normal value;
• •7. Left ventricular ejection fraction ≦ 50%;
• •8. Other concurrent and uncontrolled medical conditions considered by the investigator would affect the patient's participation in the study;
• •9. Psychiatric patients or other patients known or suspected to be unable to fully comply with the study protocol;
• •10. Pregnant or lactating women;
• •11. The researcher judged that the patients were not suitable for this study.